EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition

Xuezhi Hong iD, Yanhua Xiao, Haodong Qi, Shihao Zhu, Tim Filla, Andrea-Hermina Györfi iD, Yi-Nan Li iD, Meilin Xu, Langxian Zhi, Thuong Trinh-Minh, Clara Dees, Georg Schett iD und 2 weitere

Arthritis & Rheumatology · 2026

DOI: 10.1002/art.43440 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Arthritis & Rheumatology, 2026. Verfasst von Xuezhi Hong und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany. Hauptthemen laut MEDLINE: Linezolid, Fibroblasts, Mitochondria, Scleroderma, Systemic. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexandru-Emil Matei, Jörg H.W. Distler, Andrea-Hermina Györfi.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Beyond its role as a ribosome‐targeting antibiotic, linezolid was recently shown to modulate immune responses by inhibiting mitochondrial translation. Because mitochondrial dysfunction is implicated in various fibrotic diseases, including systemic sclerosis (SSc), this study aimed to evaluate the antifibrotic potential of linezolid and delineate its underlying mechanisms in SSc.

Methods

The effects of linezolid on fibrotic tissue remodeling were assessed using multiple experimental systems: human dermal fibroblasts, human macrophages, three‐dimensional SSc skin equivalents (SScSE), the murine model of sclerodermatous chronic graft‐versus‐host disease (sclGvHD) and precision‐cut skin slices (PCSS) obtained from patients with SSc, RNA sequencing, immunofluorescence, Western blot, and histology. Mitochondrial function was evaluated using Seahorse assays alongside mitochondrial protein synthesis assessments.

Results

Linezolid inhibited TGFβ‐induced fibroblast activation in cultured human fibroblasts, SScSE, sclGvHD mice, and SSc‐PCSS, as demonstrated by reversal of profibrotic gene expression programs, downregulation of TGFβ, WNT, and JAK‐STAT signaling, and reductions in αSMA expression or stress fiber formation, which led to reduced collagen deposition and ameliorated skin or lung fibrosis in vivo. Mechanistically, linezolid induced metabolic alterations by inhibiting mitochondrial translation in fibroblasts to hamper the oxidative phosphorylation, reduce the NAD + /NADH ratio, and down‐regulate glycolysis, an essential metabolic pathway for fibroblast activation.

Conclusion

This study provides the first evidence that inhibiting mitochondrial translation with linezolid ameliorates fibrotic tissue remodeling. Because linezolid is already clinically approved as a reserve antibiotic, these findings hold translational promise and support the use of linezolid as a novel treatment for fibrotic disorders after further validation. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LinezolidFibroblastsMitochondriaScleroderma, SystemicSkinProtein BiosynthesisAnimalsHumansFibrosisMiceDisease Models, AnimalGraft vs Host DiseaseMacrophages

Substanzen

Linezolid

Autor:innen und Institutionen

  • Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany.
  • Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University, Düsseldorf, Germany.
  • Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany.
  • Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology and Fraunhofer Cluster of Excellence for Immune-Mediated Diseases, Frankfurt am Main, Germany.

ORCID-Profile: Xuezhi Hong, Andrea-Hermina Györfi, Yi-Nan Li, Georg Schett, Alexandru-Emil Matei

Förderung

  • Alexandru-Emil Matei
  • Jörg H.W. Distler
  • Andrea-Hermina Györfi

Zitieren

APA

Hong, X., Xiao, Y., Qi, H., Zhu, S., Filla, T., Györfi, A. H., Li, Y. N., Xu, M., Zhi, L., Trinh-Minh, T., Dees, C., Schett, G., Distler, J. H. W., & Matei, A. E. (2026). Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition. Arthritis & Rheumatology. https://doi.org/10.1002/art.43440

Vancouver

Hong X, Xiao Y, Qi H, Zhu S, Filla T, Györfi AH, et al. Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition. Arthritis & Rheumatology. 2026. doi:10.1002/art.43440

BibTeX
@article{Hong2026,
  author = {Hong, Xuezhi and Xiao, Yanhua and Qi, Haodong and Zhu, Shihao and Filla, Tim and Györfi, Andrea-Hermina and Li, Yi-Nan and Xu, Meilin and Zhi, Langxian and Trinh-Minh, Thuong and Dees, Clara and Schett, Georg and Distler, Jörg H W and Matei, Alexandru-Emil},
  title = {Linezolid‐mediated Prevention of Fibroblast Activation and Tissue Fibrosis via Mitochondrial Translation Inhibition},
  journal = {Arthritis & Rheumatology},
  year = {2026},
  doi = {10.1002/art.43440}
}
Kostenlos starten →